English (UK)
中文版Dr. Amber Cai
Geneception is an innovation-driven biopharmaceutical company focusing on gene and cell therapy medicines.
Geneception Inc.
CEOMr. Yu Cai
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
Kawin
BD HEADMr. Jeff Cao
As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less
ARROWFAST
VP CHINAEric Chang
Kaitai Capital
Executive DirectorNick Cheh
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.
Far East Bio-Tec. Co., Ltd
Director of BDDenise Chen
GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ￥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.
GIG
PartnerPaul Chen
Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Reistone Biopharma
Chief of StaffLisha Chen
HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.
HEC Pharm
Senior Business Development ManagerMr Jim Chen
Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion. It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas. Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.
For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.
Responsive Web Design powered by 